Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > ALLK Allakos > Detailed Quotes

ALLK Allakos

5.160
-0.440-7.86%
Close 09/27 16:00 ET
5.000
-0.160-3.10%
Pre Mkt Price 09/28 04:21 ET
High
5.777
Open
5.710
Turnover
9.64M
Low
5.045
Pre Close
5.600
Volume
1.81M
Market Cap
437.19M
P/E(TTM)
Loss
52wk High
112.870
Shares
84.73M
P/E(Static)
Loss
52wk Low
2.535
Float Cap
317.38M
Bid/Ask %
0.00%
Historical High
157.980
Shs Float
61.51M
Volume Ratio
0.55
Historical Low
2.535
Dividend TTM
--
Div Yield TTM
--
P/B
1.96
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
2.94%
Amplitude
13.07%
Avg Price
5.325
Lot Size
1
Float Cap
317.38M
Bid/Ask %
0.00%
Historical High
157.980
Shs Float
61.51M
Volume Ratio
0.55
Historical Low
2.535
Dividend TTM
--
P/B
1.96
Dividend LFY
--
Turnover Ratio
2.94%
Amplitude
13.07%
Avg Price
5.325
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in San Carlos, CA.
CEO: Dr. Robert Alexander, PhD
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...